Increased mortality risk, which did not decrease over time, seems largely attributable to causes of death not associated with hormone treatment<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Sept. 16, 2021 (HealthDay News) — There is a substantial and persistent increased mortality risk among transgender people using hormone treatment, regardless of treatment type, according to a study published online Sept. 2 in The Lancet Diabetes & Endocrinology<\/em>.<\/p>\n Christel J.M. de Blok, M.D., from the Amsterdam University Medical Centre, and colleagues investigated trends in mortality over five decades (1972 to 2018) in a cohort of adult transgender people (2,927 transgender women and 1,641 transgender men) seen at a gender identity clinic. Information on hormone treatment was linked to national vital statistics data.<\/p>\n The researchers found that during the study period, 10.8 percent of transgender women died, which was higher than expected versus the general population of men (standardized mortality ratio [SMR], 1.8; 95 percent confidence interval [CI], 1.6 to 2.0) and the general population of women (SMR, 2.8; 95 percent CI, 2.5 to 3.1). Among transgender women, cause-specific mortality was high for cardiovascular disease, lung cancer, HIV-related disease, and suicide. A similar trend was seen among transgender men, with the number who died (2.7 percent) during the study period higher than expected versus the general population of women (SMR, 1.8; 95 percent CI, 1.3 to 2.4) but not the general population of men (SMR, 1.2; 95 percent CI, 0.9 to 1.6). In transgender men, cause-specific death was high for non-natural causes of death. During the five decades, there was no decreasing trend in mortality risk.<\/p>\n “Gender-affirming hormone treatment is thought to be safe, and most causes of death in the cohort were not related to this,” a coauthor said in a statement. “However, as there is insufficient evidence at present to determine their long-term safety, more research is needed to fully establish whether they in any way affect mortality risk for transgender people.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n